1
|
Bailey LRJ, Bugg D, Reichardt IM, Ortaç CD, Nagle A, Gunaje J, Martinson A, Johnson R, MacCoss MJ, Sakamoto T, Kelly DP, Regnier M, Davis JM. MBNL1 Regulates Programmed Postnatal Switching Between Regenerative and Differentiated Cardiac States. Circulation 2024. [PMID: 38426339 DOI: 10.1161/circulationaha.123.066860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Accepted: 02/05/2024] [Indexed: 03/02/2024]
Abstract
BACKGROUND Discovering determinants of cardiomyocyte maturity is critical for deeply understanding the maintenance of differentiated states and potentially reawakening endogenous regenerative programs in adult mammalian hearts as a therapeutic strategy. Forced dedifferentiation paired with oncogene expression is sufficient to drive cardiac regeneration, but elucidation of endogenous developmental regulators of the switch between regenerative and mature cardiomyocyte cell states is necessary for optimal design of regenerative approaches for heart disease. MBNL1 (muscleblind-like 1) regulates fibroblast, thymocyte, and erythroid differentiation and proliferation. Hence, we examined whether MBNL1 promotes and maintains mature cardiomyocyte states while antagonizing cardiomyocyte proliferation. METHODS MBNL1 gain- and loss-of-function mouse models were studied at several developmental time points and in surgical models of heart regeneration. Multi-omics approaches were combined with biochemical, histological, and in vitro assays to determine the mechanisms through which MBNL1 exerts its effects. RESULTS MBNL1 is coexpressed with a maturation-association genetic program in the heart and is regulated by the MEIS1/calcineurin signaling axis. Targeted MBNL1 overexpression early in development prematurely transitioned cardiomyocytes to hypertrophic growth, hypoplasia, and dysfunction, whereas loss of MBNL1 function increased cardiomyocyte cell cycle entry and proliferation through altered cell cycle inhibitor transcript stability. Moreover, MBNL1-dependent stabilization of estrogen-related receptor signaling was essential for maintaining cardiomyocyte maturity in adult myocytes. In accordance with these data, modulating MBNL1 dose tuned the temporal window of neonatal cardiac regeneration, where increased MBNL1 expression arrested myocyte proliferation and regeneration and MBNL1 deletion promoted regenerative states with prolonged myocyte proliferation. However, MBNL1 deficiency was insufficient to promote regeneration in the adult heart because of cell cycle checkpoint activation. CONCLUSIONS Here, MBNL1 was identified as an essential regulator of cardiomyocyte differentiated states, their developmental switch from hyperplastic to hypertrophic growth, and their regenerative potential through controlling an entire maturation program by stabilizing adult myocyte mRNAs during postnatal development and throughout adulthood. Targeting loss of cardiomyocyte maturity and downregulation of cell cycle inhibitors through MBNL1 deletion was not sufficient to promote adult regeneration.
Collapse
Affiliation(s)
- Logan R J Bailey
- Laboratory Medicine and Pathology, University of Washington, Seattle.(L.R.J.B., D.B., C.D.O., J.G., A.M., J.M.D.)
- Molecular and Cellular Biology, University of Washington, Seattle. (L.R.J.B.)
- Medical Scientist Training Program, University of Washington, Seattle. (L.R.J.B.)
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle. (L.R.J.B., D.B., I.M.R., C.D.O., A.N., J.G., A.M., M.R.)
| | - Darrian Bugg
- Laboratory Medicine and Pathology, University of Washington, Seattle.(L.R.J.B., D.B., C.D.O., J.G., A.M., J.M.D.)
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle. (L.R.J.B., D.B., I.M.R., C.D.O., A.N., J.G., A.M., M.R.)
| | - Isabella M Reichardt
- Bioengineering, University of Washington, Seattle. (I.M.R., A.N., M.R., J.M.D.)
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle. (L.R.J.B., D.B., I.M.R., C.D.O., A.N., J.G., A.M., M.R.)
| | - C Dessirée Ortaç
- Laboratory Medicine and Pathology, University of Washington, Seattle.(L.R.J.B., D.B., C.D.O., J.G., A.M., J.M.D.)
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle. (L.R.J.B., D.B., I.M.R., C.D.O., A.N., J.G., A.M., M.R.)
| | - Abigail Nagle
- Bioengineering, University of Washington, Seattle. (I.M.R., A.N., M.R., J.M.D.)
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle. (L.R.J.B., D.B., I.M.R., C.D.O., A.N., J.G., A.M., M.R.)
| | - Jagadambika Gunaje
- Laboratory Medicine and Pathology, University of Washington, Seattle.(L.R.J.B., D.B., C.D.O., J.G., A.M., J.M.D.)
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle. (L.R.J.B., D.B., I.M.R., C.D.O., A.N., J.G., A.M., M.R.)
| | - Amy Martinson
- Laboratory Medicine and Pathology, University of Washington, Seattle.(L.R.J.B., D.B., C.D.O., J.G., A.M., J.M.D.)
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle. (L.R.J.B., D.B., I.M.R., C.D.O., A.N., J.G., A.M., M.R.)
| | - Richard Johnson
- Genome Sciences, University of Washington, Seattle. (R.J., M.J.M.)
| | | | - Tomoya Sakamoto
- Cardiovascular Institute, Medicine, University of Pennsylvania, Philadelphia (T.S., D.P.K.)
| | - Daniel P Kelly
- Cardiovascular Institute, Medicine, University of Pennsylvania, Philadelphia (T.S., D.P.K.)
| | - Michael Regnier
- Bioengineering, University of Washington, Seattle. (I.M.R., A.N., M.R., J.M.D.)
- Center for Translational Muscle Research, University of Washington, Seattle. (M.R., J.M.D.)
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle. (L.R.J.B., D.B., I.M.R., C.D.O., A.N., J.G., A.M., M.R.)
| | - Jennifer M Davis
- Laboratory Medicine and Pathology, University of Washington, Seattle.(L.R.J.B., D.B., C.D.O., J.G., A.M., J.M.D.)
- Bioengineering, University of Washington, Seattle. (I.M.R., A.N., M.R., J.M.D.)
- Center for Translational Muscle Research, University of Washington, Seattle. (M.R., J.M.D.)
| |
Collapse
|
2
|
Kooiker KB, Mohran S, Turner KL, Ma W, Martinson A, Flint G, Qi L, Gao C, Zheng Y, McMillen TS, Mandrycky C, Mahoney-Schaefer M, Freeman JC, Costales Arenas EG, Tu AY, Irving TC, Geeves MA, Tanner BC, Regnier M, Davis J, Moussavi-Harami F. Danicamtiv Increases Myosin Recruitment and Alters Cross-Bridge Cycling in Cardiac Muscle. Circ Res 2023; 133:430-443. [PMID: 37470183 PMCID: PMC10434831 DOI: 10.1161/circresaha.123.322629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2023] [Revised: 07/10/2023] [Accepted: 07/13/2023] [Indexed: 07/21/2023]
Abstract
BACKGROUND Modulating myosin function is a novel therapeutic approach in patients with cardiomyopathy. Danicamtiv is a novel myosin activator with promising preclinical data that is currently in clinical trials. While it is known that danicamtiv increases force and cardiomyocyte contractility without affecting calcium levels, detailed mechanistic studies regarding its mode of action are lacking. METHODS Permeabilized porcine cardiac tissue and myofibrils were used for X-ray diffraction and mechanical measurements. A mouse model of genetic dilated cardiomyopathy was used to evaluate the ability of danicamtiv to correct the contractile deficit. RESULTS Danicamtiv increased force and calcium sensitivity via increasing the number of myosins in the ON state and slowing cross-bridge turnover. Our detailed analysis showed that inhibition of ADP release results in decreased cross-bridge turnover with cross bridges staying attached longer and prolonging myofibril relaxation. Danicamtiv corrected decreased calcium sensitivity in demembranated tissue, abnormal twitch magnitude and kinetics in intact cardiac tissue, and reduced ejection fraction in the whole organ. CONCLUSIONS As demonstrated by the detailed studies of Danicamtiv, increasing myosin recruitment and altering cross-bridge cycling are 2 mechanisms to increase force and calcium sensitivity in cardiac muscle. Myosin activators such as Danicamtiv can treat the causative hypocontractile phenotype in genetic dilated cardiomyopathy.
Collapse
Affiliation(s)
- Kristina B. Kooiker
- Division of Cardiology, Medicine (K.B.K., M.M.-S., J.C.F., E.G.C.A., F.M.-H.), University of Washington
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Center for Cardiovascular Biology (K.B.K., A.M., M.R., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
| | - Saffie Mohran
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Bioengineering (S.M., A.M., G.F., C.M., A.-Y.T., M.R., J.D.), University of Washington
| | - Kyrah L. Turner
- School of Molecular Biosciences, Washington State University (K.L.T.)
| | - Weikang Ma
- Department of Biology, Illinois Institute of Technology, Chicago (W.M., L.Q., T.C.I.)
| | - Amy Martinson
- Center for Cardiovascular Biology (K.B.K., A.M., M.R., J.D., F.M.-H.), University of Washington
- Department of Laboratory Medicine and Pathology (A.M., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Bioengineering (S.M., A.M., G.F., C.M., A.-Y.T., M.R., J.D.), University of Washington
| | - Galina Flint
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Bioengineering (S.M., A.M., G.F., C.M., A.-Y.T., M.R., J.D.), University of Washington
| | - Lin Qi
- Department of Biology, Illinois Institute of Technology, Chicago (W.M., L.Q., T.C.I.)
| | - Chengqian Gao
- College of Basic Medical Sciences, Dalian Medical University, Liaoning, China (C.G., Y.Z.)
| | - Yahan Zheng
- College of Basic Medical Sciences, Dalian Medical University, Liaoning, China (C.G., Y.Z.)
| | - Timothy S. McMillen
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Anesthesiology and Pain Medicine (T.S.M.), University of Washington
| | - Christian Mandrycky
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Bioengineering (S.M., A.M., G.F., C.M., A.-Y.T., M.R., J.D.), University of Washington
| | - Max Mahoney-Schaefer
- Division of Cardiology, Medicine (K.B.K., M.M.-S., J.C.F., E.G.C.A., F.M.-H.), University of Washington
| | - Jeremy C. Freeman
- Division of Cardiology, Medicine (K.B.K., M.M.-S., J.C.F., E.G.C.A., F.M.-H.), University of Washington
| | | | - An-Yu Tu
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Bioengineering (S.M., A.M., G.F., C.M., A.-Y.T., M.R., J.D.), University of Washington
| | - Thomas C. Irving
- Department of Biology, Illinois Institute of Technology, Chicago (W.M., L.Q., T.C.I.)
| | - Michael A. Geeves
- School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, United Kingdom (M.A.G.)
| | - Bertrand C.W. Tanner
- Department of Integrative Physiology and Neuroscience, Washington State University (B.C.W.T.)
| | - Michael Regnier
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Center for Cardiovascular Biology (K.B.K., A.M., M.R., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Bioengineering (S.M., A.M., G.F., C.M., A.-Y.T., M.R., J.D.), University of Washington
| | - Jennifer Davis
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Center for Cardiovascular Biology (K.B.K., A.M., M.R., J.D., F.M.-H.), University of Washington
- Department of Laboratory Medicine and Pathology (A.M., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Department of Bioengineering (S.M., A.M., G.F., C.M., A.-Y.T., M.R., J.D.), University of Washington
| | - Farid Moussavi-Harami
- Division of Cardiology, Medicine (K.B.K., M.M.-S., J.C.F., E.G.C.A., F.M.-H.), University of Washington
- Center of Translational Muscle Research (K.B.K., S.M., G.F., T.S.M., C.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
- Center for Cardiovascular Biology (K.B.K., A.M., M.R., J.D., F.M.-H.), University of Washington
- Department of Laboratory Medicine and Pathology (A.M., J.D., F.M.-H.), University of Washington
- Institute for Stem Cell & Regenerative Medicine (K.B.K., S.M., A.M., T.S.M., A.-Y.T., M.R., J.D., F.M.-H.), University of Washington
| |
Collapse
|
3
|
Mhatre KN, Mathieu J, Martinson A, Flint G, Blakley LP, Tabesh A, Reinecke H, Yang X, Guan X, Murali E, Klaiman JM, Odom GL, Brown MB, Tian R, Hauschka SD, Raftery D, Moussavi-Harami F, Regnier M, Murry CE. Cell based dATP delivery as a therapy for chronic heart failure. bioRxiv 2023:2023.04.24.538108. [PMID: 37162854 PMCID: PMC10168250 DOI: 10.1101/2023.04.24.538108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Transplanted human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) improve ventricular performance when delivered acutely post-myocardial infarction but are ineffective in chronic myocardial infarction/heart failure. 2'-deoxy-ATP (dATP) activates cardiac myosin and potently increases contractility. Here we engineered hPSC-CMs to overexpress ribonucleotide reductase, the enzyme controlling dATP production. In vivo, dATP-producing CMs formed new myocardium that transferred dATP to host cardiomyocytes via gap junctions, increasing their dATP levels. Strikingly, when transplanted into chronically infarcted hearts, dATP-producing grafts increased left ventricular function, whereas heart failure worsened with wild-type grafts or vehicle injections. dATP-donor cells recipients had greater voluntary exercise, improved cardiac metabolism, reduced pulmonary congestion and pathological cardiac hypertrophy, and improved survival. This combination of remuscularization plus enhanced host contractility offers a novel approach to treating the chronically failing heart.
Collapse
Affiliation(s)
- Ketaki N Mhatre
- Institute for Stem Cell and Regenerative Medicine, University of Washington; Seattle, WA 98109, USA
- Department of Bioengineering, University of Washington; Seattle, WA 98195, USA
- Department of Laboratory Medicine & Pathology, University of Washington; Seattle, WA 98195, USA
| | - Julie Mathieu
- Institute for Stem Cell and Regenerative Medicine, University of Washington; Seattle, WA 98109, USA
- Department of Comparative Medicine, University of Washington; Seattle, WA 98195, USA
| | - Amy Martinson
- Institute for Stem Cell and Regenerative Medicine, University of Washington; Seattle, WA 98109, USA
- Center for Cardiovascular Biology, University of Washington; Seattle, WA 98109, USA
- Department of Laboratory Medicine & Pathology, University of Washington; Seattle, WA 98195, USA
| | - Galina Flint
- Department of Bioengineering, University of Washington; Seattle, WA 98195, USA
- Center for Translational Muscle Research, University of Washington; Seattle, WA 98109, USA
| | - Leslie P Blakley
- Institute for Stem Cell and Regenerative Medicine, University of Washington; Seattle, WA 98109, USA
- Center for Cardiovascular Biology, University of Washington; Seattle, WA 98109, USA
- Department of Laboratory Medicine & Pathology, University of Washington; Seattle, WA 98195, USA
| | - Arash Tabesh
- Institute for Stem Cell and Regenerative Medicine, University of Washington; Seattle, WA 98109, USA
- Department of Laboratory Medicine & Pathology, University of Washington; Seattle, WA 98195, USA
| | - Hans Reinecke
- Institute for Stem Cell and Regenerative Medicine, University of Washington; Seattle, WA 98109, USA
- Center for Cardiovascular Biology, University of Washington; Seattle, WA 98109, USA
- Department of Laboratory Medicine & Pathology, University of Washington; Seattle, WA 98195, USA
| | - Xiulan Yang
- Institute for Stem Cell and Regenerative Medicine, University of Washington; Seattle, WA 98109, USA
- Center for Cardiovascular Biology, University of Washington; Seattle, WA 98109, USA
- Department of Laboratory Medicine & Pathology, University of Washington; Seattle, WA 98195, USA
| | - Xuan Guan
- Department of Bioengineering, University of Washington; Seattle, WA 98195, USA
| | - Eesha Murali
- Institute for Stem Cell and Regenerative Medicine, University of Washington; Seattle, WA 98109, USA
- Department of Bioengineering, University of Washington; Seattle, WA 98195, USA
| | - Jordan M Klaiman
- Institute for Stem Cell and Regenerative Medicine, University of Washington; Seattle, WA 98109, USA
- Center for Cardiovascular Biology, University of Washington; Seattle, WA 98109, USA
- Department of Laboratory Medicine & Pathology, University of Washington; Seattle, WA 98195, USA
| | - Guy L Odom
- Institute for Stem Cell and Regenerative Medicine, University of Washington; Seattle, WA 98109, USA
- Center for Cardiovascular Biology, University of Washington; Seattle, WA 98109, USA
- Center for Translational Muscle Research, University of Washington; Seattle, WA 98109, USA
- Department of Neurology, University of Washington; Seattle, WA 98195, USA
| | - Mary Beth Brown
- Center for Translational Muscle Research, University of Washington; Seattle, WA 98109, USA
- Division of Physical Therapy, Department of Rehabilitation Medicine, University of Washington; Seattle, WA 98195, USA
| | - Rong Tian
- Center for Translational Muscle Research, University of Washington; Seattle, WA 98109, USA
- Department of Anesthesiology and Pain Medicine, University of Washington; Seattle, WA 98195, USA
- The Mitochondria and Metabolism Center (MMC), University of Washington; Seattle, WA 98109, USA
| | - Stephen D Hauschka
- Institute for Stem Cell and Regenerative Medicine, University of Washington; Seattle, WA 98109, USA
- Center for Translational Muscle Research, University of Washington; Seattle, WA 98109, USA
- Department of Biochemistry, University of Washington; Seattle, WA 98195, USA
| | - Daniel Raftery
- Department of Anesthesiology and Pain Medicine, University of Washington; Seattle, WA 98195, USA
- The Mitochondria and Metabolism Center (MMC), University of Washington; Seattle, WA 98109, USA
- Northwest Metabolomics Research Center, University of Washington; Seattle, WA 98109, USA
| | - Farid Moussavi-Harami
- Institute for Stem Cell and Regenerative Medicine, University of Washington; Seattle, WA 98109, USA
- Center for Cardiovascular Biology, University of Washington; Seattle, WA 98109, USA
- Department of Laboratory Medicine & Pathology, University of Washington; Seattle, WA 98195, USA
- Center for Translational Muscle Research, University of Washington; Seattle, WA 98109, USA
- Division of Cardiology, University of Washington; Seattle, WA 98195, USA
| | - Michael Regnier
- Institute for Stem Cell and Regenerative Medicine, University of Washington; Seattle, WA 98109, USA
- Department of Bioengineering, University of Washington; Seattle, WA 98195, USA
- Center for Cardiovascular Biology, University of Washington; Seattle, WA 98109, USA
- Center for Translational Muscle Research, University of Washington; Seattle, WA 98109, USA
- Department of Physiology and Biophysics, University of Washington; Seattle, WA 98195, USA
| | - Charles E Murry
- Institute for Stem Cell and Regenerative Medicine, University of Washington; Seattle, WA 98109, USA
- Department of Bioengineering, University of Washington; Seattle, WA 98195, USA
- Center for Cardiovascular Biology, University of Washington; Seattle, WA 98109, USA
- Department of Laboratory Medicine & Pathology, University of Washington; Seattle, WA 98195, USA
- Center for Translational Muscle Research, University of Washington; Seattle, WA 98109, USA
- Division of Cardiology, University of Washington; Seattle, WA 98195, USA
| |
Collapse
|
4
|
Kooiker KB, Mohran S, Turner KL, Ma W, Flint G, Qi L, Gao C, Zheng Y, McMillen TS, Mandrycky C, Martinson A, Mahoney-Schaefer M, Freeman JC, Costales Arenas EG, Tu AY, Irving TC, Geeves MA, Tanner BCW, Regnier M, Davis J, Moussavi-Harami F. Danicamtiv increases myosin recruitment and alters the chemomechanical cross bridge cycle in cardiac muscle. bioRxiv 2023:2023.01.31.526380. [PMID: 36778318 PMCID: PMC9915609 DOI: 10.1101/2023.01.31.526380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Modulating myosin function is a novel therapeutic approach in patients with cardiomyopathy. Detailed mechanism of action of these agents can help predict potential unwanted affects and identify patient populations that can benefit most from them. Danicamtiv is a novel myosin activator with promising preclinical data that is currently in clinical trials. While it is known danicamtiv increases force and cardiomyocyte contractility without affecting calcium levels, detailed mechanistic studies regarding its mode of action are lacking. Using porcine cardiac tissue and myofibrils we demonstrate that Danicamtiv increases force and calcium sensitivity via increasing the number of myosin in the "on" state and slowing cross bridge turnover. Our detailed analysis shows that inhibition of ADP release results in decreased cross bridge turnover with cross bridges staying on longer and prolonging myofibril relaxation. Using a mouse model of genetic dilated cardiomyopathy, we demonstrated that Danicamtiv corrected calcium sensitivity in demembranated and abnormal twitch magnitude and kinetics in intact cardiac tissue. Significance Statement Directly augmenting sarcomere function has potential to overcome limitations of currently used inotropic agents to improve cardiac contractility. Myosin modulation is a novel mechanism for increased contraction in cardiomyopathies. Danicamtiv is a myosin activator that is currently under investigation for use in cardiomyopathy patients. Our study is the first detailed mechanism of how Danicamtiv increases force and alters kinetics of cardiac activation and relaxation. This new understanding of the mechanism of action of Danicamtiv can be used to help identify patients that could benefit most from this treatment.
Collapse
|
5
|
Bretherton RC, Reichardt IM, Zabrecky KA, Goldstein AJ, Bailey LR, Bugg D, McMillen TS, Kooiker KB, Flint GV, Martinson A, Gunaje J, Koser F, Plaster E, Linke WA, Regnier M, Moussavi-Harami F, Sniadecki NJ, DeForest CA, Davis J. Correcting dilated cardiomyopathy with fibroblast-targeted p38 deficiency. bioRxiv 2023:2023.01.23.523684. [PMID: 36747691 PMCID: PMC9900749 DOI: 10.1101/2023.01.23.523684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Inherited mutations in contractile and structural genes, which decrease cardiomyocyte tension generation, are principal drivers of dilated cardiomyopathy (DCM)- the leading cause of heart failure 1,2 . Progress towards developing precision therapeutics for and defining the underlying determinants of DCM has been cardiomyocyte centric with negligible attention directed towards fibroblasts despite their role in regulating the best predictor of DCM severity, cardiac fibrosis 3,4 . Given that failure to reverse fibrosis is a major limitation of both standard of care and first in class precision therapeutics for DCM, this study examined whether cardiac fibroblast-mediated regulation of the heart's material properties is essential for the DCM phenotype. Here we report in a mouse model of inherited DCM that prior to the onset of fibrosis and dilated myocardial remodeling both the myocardium and extracellular matrix (ECM) stiffen from switches in titin isoform expression, enhanced collagen fiber alignment, and expansion of the cardiac fibroblast population, which we blocked by genetically suppressing p38α in cardiac fibroblasts. This fibroblast-targeted intervention unexpectedly improved the primary cardiomyocyte defect in contractile function and reversed ECM and dilated myocardial remodeling. Together these findings challenge the long-standing paradigm that ECM remodeling is a secondary complication to inherited defects in cardiomyocyte contractile function and instead demonstrate cardiac fibroblasts are essential contributors to the DCM phenotype, thus suggesting DCM-specific therapeutics will require fibroblast-specific strategies.
Collapse
|
6
|
Ong L, Colzani M, Mitzelfelt K, Gambardella L, Bertero A, Martinson A, Murry C, Sinha S. Could Cellular Therapy Rescue the Chronically Failing Heart? J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
7
|
Kooiker KB, Berisha D, Martinson A, Tudor J, Freeman J, Branley C, Moussavi-Harami F. Ribonucleotide Reductase is Essential in Adult Cardiomyocytes. Biophys J 2020. [DOI: 10.1016/j.bpj.2019.11.1494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
8
|
Bargehr J, Ong LP, Colzani M, Davaapil H, Hofsteen P, Bhandari S, Gambardella L, Le Novère N, Iyer D, Sampaziotis F, Weinberger F, Bertero A, Leonard A, Bernard WG, Martinson A, Figg N, Regnier M, Bennett MR, Murry CE, Sinha S. Epicardial cells derived from human embryonic stem cells augment cardiomyocyte-driven heart regeneration. Nat Biotechnol 2019; 37:895-906. [PMID: 31375810 PMCID: PMC6824587 DOI: 10.1038/s41587-019-0197-9] [Citation(s) in RCA: 118] [Impact Index Per Article: 23.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Accepted: 06/24/2019] [Indexed: 02/02/2023]
Abstract
The epicardium and its derivatives provide trophic and structural support for the developing and adult heart. Here we tested the ability of human embryonic stem cell (hESC)-derived epicardium to augment the structure and function of engineered heart tissue in vitro and to improve efficacy of hESC-cardiomyocyte grafts in infarcted athymic rat hearts. Epicardial cells markedly enhanced the contractility, myofibril structure and calcium handling of human engineered heart tissues, while reducing passive stiffness compared with mesenchymal stromal cells. Transplanted epicardial cells formed persistent fibroblast grafts in infarcted hearts. Cotransplantation of hESC-derived epicardial cells and cardiomyocytes doubled graft cardiomyocyte proliferation rates in vivo, resulting in 2.6-fold greater cardiac graft size and simultaneously augmenting graft and host vascularization. Notably, cotransplantation improved systolic function compared with hearts receiving either cardiomyocytes alone, epicardial cells alone or vehicle. The ability of epicardial cells to enhance cardiac graft size and function makes them a promising adjuvant therapeutic for cardiac repair.
Collapse
Affiliation(s)
- Johannes Bargehr
- The Anne McLaren Laboratory, Wellcome Trust - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Lay Ping Ong
- The Anne McLaren Laboratory, Wellcome Trust - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Maria Colzani
- The Anne McLaren Laboratory, Wellcome Trust - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Hongorzul Davaapil
- The Anne McLaren Laboratory, Wellcome Trust - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Peter Hofsteen
- Department of Pathology, Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA
| | - Shiv Bhandari
- Department of Pathology, Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA
| | - Laure Gambardella
- The Anne McLaren Laboratory, Wellcome Trust - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | | | - Dharini Iyer
- The Anne McLaren Laboratory, Wellcome Trust - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Fotios Sampaziotis
- The Anne McLaren Laboratory, Wellcome Trust - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
| | - Florian Weinberger
- Department of Pathology, Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA
| | - Alessandro Bertero
- Department of Pathology, Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA
| | - Andrea Leonard
- Department of Pathology, Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA
| | - William G Bernard
- The Anne McLaren Laboratory, Wellcome Trust - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Amy Martinson
- Department of Pathology, Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA
| | - Nichola Figg
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Michael Regnier
- Department of Bioengineering, University of Washington, Seattle, WA, USA
| | - Martin R Bennett
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Charles E Murry
- Department of Pathology, Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA.
- Department of Bioengineering, University of Washington, Seattle, WA, USA.
- Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA.
| | - Sanjay Sinha
- The Anne McLaren Laboratory, Wellcome Trust - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK.
| |
Collapse
|
9
|
Redd MA, Zeinstra N, Qin W, Wei W, Martinson A, Wang Y, Wang RK, Murry CE, Zheng Y. Patterned human microvascular grafts enable rapid vascularization and increase perfusion in infarcted rat hearts. Nat Commun 2019; 10:584. [PMID: 30718840 PMCID: PMC6362250 DOI: 10.1038/s41467-019-08388-7] [Citation(s) in RCA: 85] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2017] [Accepted: 01/04/2019] [Indexed: 12/23/2022] Open
Abstract
Vascularization and efficient perfusion are long-standing challenges in cardiac tissue engineering. Here we report engineered perfusable microvascular constructs, wherein human embryonic stem cell-derived endothelial cells (hESC-ECs) are seeded both into patterned microchannels and the surrounding collagen matrix. In vitro, the hESC-ECs lining the luminal walls readily sprout and anastomose with de novo-formed endothelial tubes in the matrix under flow. When implanted on infarcted rat hearts, the perfusable microvessel grafts integrate with coronary vasculature to a greater degree than non-perfusable self-assembled constructs at 5 days post-implantation. Optical microangiography imaging reveal that perfusable grafts have 6-fold greater vascular density, 2.5-fold higher vascular velocities and >20-fold higher volumetric perfusion rates. Implantation of perfusable grafts containing additional hESC-derived cardiomyocytes show higher cardiomyocyte and vascular density. Thus, pre-patterned vascular networks enhance vascular remodeling and accelerate coronary perfusion, potentially supporting cardiac tissues after implantation. These findings should facilitate the next generation of cardiac tissue engineering design.
Collapse
Affiliation(s)
- Meredith A Redd
- Department of Bioengineering, University of Washington, Seattle, WA, 98109, USA
- Center for Cardiovascular Biology, University of Washington, Seattle, WA, 98109, USA
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, 98109, USA
| | - Nicole Zeinstra
- Department of Bioengineering, University of Washington, Seattle, WA, 98109, USA
- Center for Cardiovascular Biology, University of Washington, Seattle, WA, 98109, USA
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, 98109, USA
| | - Wan Qin
- Department of Bioengineering, University of Washington, Seattle, WA, 98109, USA
| | - Wei Wei
- Department of Bioengineering, University of Washington, Seattle, WA, 98109, USA
| | - Amy Martinson
- Center for Cardiovascular Biology, University of Washington, Seattle, WA, 98109, USA
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, 98109, USA
- Department of Pathology, University of Washington, Seattle, WA, 98109, USA
| | - Yuliang Wang
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, 98109, USA
- Paul G. Allen School of Computer Science & Engineering, University of Washington, Seattle, WA, 98109, USA
| | - Ruikang K Wang
- Department of Bioengineering, University of Washington, Seattle, WA, 98109, USA
| | - Charles E Murry
- Department of Bioengineering, University of Washington, Seattle, WA, 98109, USA.
- Center for Cardiovascular Biology, University of Washington, Seattle, WA, 98109, USA.
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, 98109, USA.
- Department of Pathology, University of Washington, Seattle, WA, 98109, USA.
- Department of Medicine/Cardiology, University of Washington, Seattle, WA, 98109, USA.
| | - Ying Zheng
- Department of Bioengineering, University of Washington, Seattle, WA, 98109, USA.
- Center for Cardiovascular Biology, University of Washington, Seattle, WA, 98109, USA.
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, 98109, USA.
| |
Collapse
|
10
|
Montgomery J, Martinson A. Partnering with Music Therapists: A Model for Addressing Students' Musical and Extramusical Goals. ACTA ACUST UNITED AC 2016. [DOI: 10.2307/3401110] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Janet Montgomery
- Arts coordinator for the Denver Public Schools in Colorado. She can be reached at
| | - Amy Martinson
- Doctoral candidate at the University of Colorado at Boulder and music specialist at Edwina Fallis Elementary School in Denver, Colorado. She can be reached at
| |
Collapse
|
11
|
Semchuk W, Martinson A, Evans C, Blackburn D, Zimmerman R, Patel T. 428 Impact of a collaborative care model in a medication-optimization program, the saskatchewan medication assessment for risk reduction target therapies (SMART2) program: A prospective, randomized, controlled study. Can J Cardiol 2011. [DOI: 10.1016/j.cjca.2011.07.362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
|
12
|
Abstract
The effects on rat fetuses of a single intrauterine injection of long-acting insulin with respect to length, body and organ weights, total lipids, phospholipids, cholesterol, neutral fat, total nitrogen and water content were investigated. At the age of 498 hours the fetuses were injected in utero with 2 IU of long-acting insulin or a control solution. Twenty-four hours after the injections the insulin-treated fetuses weighed about 10 per cent more than the control fetuses, 5.32 +/- 0.05 g (75 fetuses) and 4.85 +/- 0.05 (73 fetuses) respectively (p less than 0.001). The body lengths were 54.1 +/- 0.2 mm and 52.9 +/- 0.2 mm respectively (p less than 0.001). The insulin-treated fetuses had higher organ weights and higher content of total lipids, phospholipids and neutral fat. The amount of total lipids was higher in insulin-treated fetuses even after taking into account differences in body weight, suggesting that the insulin-treated fetuses were obese. The finding of significantly lower water content in insulin-treated fetuses at equal body weight is consistent with the higher fat content. There was no increase in total nitrogen or length in the fetuses in the insulin-treated group compared to control fetuses at equal body weight indicating that the administered insulin mobilized maternal proteins and that protein, as well as length, increased proportionately to overweight. For quantitative analysis of morphological and biochemical variables dependent upon body weight, as in this investigation, multivariate analysis is indispensable.
Collapse
|